Opko Health, Inc. (OPK): Gamma Investments Trust Frost , CEO of Opko Health, Inc. purchased 21,000 shares on Jun 27, 2016. The Insider buying transaction was reported by the company on Jun 28, 2016 to the Securities and Exchange Commission. The shares were purchased at $8.90 per share for a total value of $186,383.50 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 27, 2016, Gamma Investments Trust Frost (CEO) purchased 18,000 shares at $9.41 per share price.On May 17, 2016, Robert A Baron (director) sold 37,500 shares at $9.83 per share price.Also, On Mar 18, 2016, Jane Ph D Hsiao (Vice Chairman & CTO) purchased 1,200 shares at $10.65 per share price.On Sep 15, 2015, Adam Logal (CFO) purchased 1,000 shares at $9.95 per share price.
Shares of Opko Health (OPK) ended Monday, Jun 27, 2016 session in red amid volatile trading. The shares closed down -0.64 points or -6.77% at $8.82 with 55,77,340 shares getting traded. Post opening the session at $9.28, the shares hit an intraday low of $8.7099 and an intraday high of $9.38 and the price vacillated in this range throughout the day. The company has a market cap of $4,828 M and the number of outstanding shares has been calculated to be 54,74,44,350 shares. The 52-week high of Opko Health is $17.51 and the 52-week low is $7.1225.
Company has been under the radar of several Street Analysts.Opko Health is Reiterated by Standpoint Research to Buy and the brokerage firm has raised the Price Target to $ 18 from a previous price target of $16 .The Rating was issued on Jun 21, 2016.Opko Health is Initiated by Standpoint Research to Buy and the brokerage firm has set the Price Target at $16. The Rating was issued on Jun 3, 2016.Opko Health is Reiterated by Barrington Research to Outperform while Lowering the Price Target of the company shares to $ 16 from a previous price target of $17 . The Rating was issued on Mar 31, 2016.
OPKO Health Inc. (OPKO) is a biopharmaceutical and diagnostics company. The Company is involved in developing a range of solutions to diagnose treat and prevent various conditions including point-of-care tests laboratory developed tests (LDTs) molecular diagnostics tests and pharmaceuticals and vaccines. It operates in two segments: pharmaceutical and diagnostics. Its pharmaceutical segment consists of two operating segments pharmaceutical research and development segment and pharmaceutical operations. Its diagnostics segment consists of pathology operations and point-of-care and molecular diagnostics operations. It owns pharmaceutical operations in Chile Spain Mexico Israel Uruguay and Brazil. The product pipeline includes several pharmaceutical compounds and technologies in research and development for a range of indications and conditions.